Esperion Therapeutics, Inc. (ESPR)

33.95
1.17 3.33
NASDAQ
Prev Close 35.12
Open 35.22
Day Low/High 33.59 / 35.22
52 Wk Low/High 24.82 / 76.98
Volume 532.63K
Exchange NASDAQ
Shares Outstanding 27.83B
Market Cap 966.10M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Watch These Biotech Names on Strong Earnings

Watch These Biotech Names on Strong Earnings

Merger activity is the number 1 driver I am watching for biotech growth.

Frustration Levels Are High, but This Is Constructive Market Action

Frustration Levels Are High, but This Is Constructive Market Action

Strong markets tend to stay sticky to the upside, and the mild pressure on the indices isn't preventing some good stock picking.

IBM's Pricey Red Hat Deal Helps Put Pep in Market's Step

IBM's Pricey Red Hat Deal Helps Put Pep in Market's Step

There is much talk that IBM is overpaying for Red Hat, but this deal is a net positive for the market as a whole.

Biotechs Remain the Best Place For Stock Picking

Biotechs Remain the Best Place For Stock Picking

Biotech companies show more energy than the rest of the market Monday.

It's Time to Bring the Heat

It's Time to Bring the Heat

I'm starting a new periodic feature that will bring you the hottest-trading stocks I see.

Better Breadth, But a Tired Close

Buyers were hesitant to keep pressing as the day wrapped up.

Bulls Steadfast, but Market Players Skittish

Bulls Steadfast, but Market Players Skittish

Not a big day of gains, but there is underlying support.

Market Has a Mood Swing to the Upside

Gloom is gone as likelihood of Fed rate hike fades.

Flow of Bad News Pours Over Market

Flow of Bad News Pours Over Market

Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.

Troubled Stocks Go From Worst to First

Troubled Stocks Go From Worst to First

Oil- and commodity-related shares perform well.

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.

A Down Day, But No Cause for Alarm

Thin volume likely ahead of holiday weekend.

This Isn't What This Market Needs

A flood of supply in a nervous market isn't a good idea.

Backing Away From Biotechs

This sector could see some real damage.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

These Stocks Get Benefit of the Doubt

Market backtracks on skepticism over biotechs.

Looking Back to Go Forward

Looking Back to Go Forward

For Bluebird Bio and Esperion, the charts tell the whole story.

Remarkable Biotech Runs Continue

Remarkable Biotech Runs Continue

A Fed-related dip may be your only hope to get in lower.

What Is Wrong With You People?

What Is Wrong With You People?

These companies are doing great -- take some profits!

How I Deal with Gap-Up Trades

How I Deal with Gap-Up Trades

A tale of two stocks with Esperion and DSW.

Momentum Is Not Dead

The chasing in certain areas was intense.

Damage to Indices Was Fairly Minimal

But stay disciplined, honor your stops and protect gains.

NanoString Best BioTech IPO

NanoString Best BioTech IPO

Three biotech companies are going public this week and NanoString looks better than Prosensa or Esperion says Francis Gaskins.